{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:07:26Z","timestamp":1761541646345,"version":"3.40.5"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T00:00:00Z","timestamp":1651968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Desmopressin can be used to prevent bleeding in von Willebrand disease (VWD), but the relationship between desmopressin and von Willebrand factor activity (VWF:Act) has yet to be quantified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To quantify the relationship between desmopressin dose, its plasma concentration and the VWF:Act response in type 1 VWD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Forty\u2010seven VWD patients (median age 25 years, IQR: 19\u201337; median body weight 71\u00a0kg, IQR: 59\u201386) received an IV desmopressin dose of .3 mcg\/kg. In total, 177 blood samples were available for analysis. We developed an integrated population pharmacokinetic\u2010pharmacodynamic (PK\u2010PD) model using nonlinear mixed effect modelling. Subsequently, we performed Monte Carlo simulations to investigate the efficacy of the current dosing regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A one\u2010compartment PK model best described the time profile of the desmopressin concentrations. In the PD turnover model, the relationship between desmopressin plasma concentration and release of VWF:Act from the vascular endothelium was best described with an Emax model. Typically, VWF:Act increased 452% with an EC50 of .174\u00a0ng\/ml. Simulations demonstrated that after .3 mcg\/kg desmopressin intravenously, &gt;90% patients with a VWF:Act baseline of \u2265.20 IU\/mL attain a VWF:Act &gt;.5 IU\/ml up to \u22654\u00a0h after administration. A capped dose of 30 mcg was sufficient in patients weighing over 100\u00a0kg.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The relationship between desmopressin and VWF:Act was quantified in a PK\u2010PD model. The simulations provide evidence that recently published international guidelines advising an intravenous desmopressin dose of .3 mcg\/kg with a capped dose of 30 mcg\u00a0&gt;\u00a0100\u00a0kg gives a sufficient desmopressin response.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14582","type":"journal-article","created":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T14:44:51Z","timestamp":1652021091000},"page":"814-821","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Quantification of the relationship between desmopressin concentration and Von Willebrand factor in Von Willebrand disease type 1: A pharmacodynamic study"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1069-8097","authenticated-orcid":false,"given":"Jessica M.","family":"Heijdra","sequence":"first","affiliation":[{"name":"Department of Paediatric Haematology Erasmus MC Sophia Children's Hospital University Medical Centre Rotterdam  The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2810-1570","authenticated-orcid":false,"given":"Michael E.","family":"Cloesmeijer","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy \u2013 Clinical Pharmacology Amsterdam UMC University of Amsterdam  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nico C.B.","family":"de Jager","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy \u2013 Clinical Pharmacology Amsterdam UMC University of Amsterdam  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-1371","authenticated-orcid":false,"given":"Frank W.G.","family":"Leebeek","sequence":"additional","affiliation":[{"name":"Department of Haematology Erasmus MC Erasmus University Medical Centre Rotterdam  The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0265-4871","authenticated-orcid":false,"given":"Marieke H.J.A.","family":"Kruip","sequence":"additional","affiliation":[{"name":"Department of Haematology Erasmus MC Erasmus University Medical Centre Rotterdam  The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjon H.","family":"Cnossen","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology Erasmus MC Sophia Children's Hospital University Medical Centre Rotterdam  The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron A.A.","family":"Math\u00f4t","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy \u2013 Clinical Pharmacology Amsterdam UMC University of Amsterdam  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the OPTI\u2010CLOT\/ To WiN study group and SYMPHONY consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,5,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1601561"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02146.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003264"},{"key":"e_1_2_9_5_1","article-title":"Desmopressin \u2013 a haemostatic drug: state\u2010of\u2010the\u2010art review","volume":"14","author":"Lethagen S","year":"1997","journal-title":"Eur J Anaesthesiol | EJA"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1975.tb00521.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-199701000-00002"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0793-2"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25928"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.71"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12732"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1714349"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1646051"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061691"},{"issue":"11","key":"e_1_2_9_16_1","first-page":"1254","article-title":"Sex\u2010based differences in drug activity","volume":"80","author":"Whitley H","year":"2009","journal-title":"Am Fam Physician"},{"issue":"2","key":"e_1_2_9_17_1","first-page":"s9","article-title":"Treatment of von Willebrand disease with FVIII\/VWF concentrates","volume":"9","author":"Castaman G","year":"2011","journal-title":"Blood Transfus"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620715587879"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-122945"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12586"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjae.2018.09.001"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14582","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14582","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T08:44:09Z","timestamp":1692693849000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,8]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/hae.14582"],"URL":"https:\/\/doi.org\/10.1111\/hae.14582","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"type":"print","value":"1351-8216"},{"type":"electronic","value":"1365-2516"}],"subject":[],"published":{"date-parts":[[2022,5,8]]},"assertion":[{"value":"2021-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}